Intimation of completion of inspection by the United States Food and Drug Administration (USFDA) at the Company''s Facilty.

Wanbury Limited Re?d. Office: BSEL Tech Park, B-wing 1O ' Floor, Sector-30 A, Opp. Vashi Railway Station, Vashi Navi Mumbai 400 703 Maharashtra, INDIA Tel. : +91-22-6794 2222 +91-22-7196 3222 ( WANBURY CIN L51900MH1988PLC04B455 Email : info@wanbury.com Website: vvww.waribury.com July 22, 2026 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Dalal Street, Exchange Plaza, Bandra Kurla Complex Mumbai-400 001. Bandra (East), Mumbai 400 051 Scrip Code: 524212 Scrip Code: W ANBURY Dear Sir, Sub.: Intimation of completion of inspection by the United States Food and Drug Administration (USFDA) at the Company's facility at Tanuku, West Godavari District, Andhra Pradesh Further to our letter dated 20th July, 2026, we hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the company's facility at Tanuku, West Godavari District, Andra Pradesh during the period from July 13, 2026 to July 17, 2026. At the conclusion of the inspection, the USFDA has issued a Form 483 with six observations. The Company will respond to these observations to FDA within the stipulated time. The relevant disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/ 49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are provided in ANNE:XURE - I below. We will keep the stock exchanges informed if there is any further update in this matter. Please take the above information on record. Thanking you, Yours truly For Wanbury Limited Jitendra J Gandhi Company Secretary Encl.: afa. WAN BURY ANNEXURE-1 Details of the action initiated by USFDA in the prescribed format as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/ 49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026: Particulars Details United States Food and Drug Administration 1. Name of the authority (USFDA), USA. The United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) inspection at the Company's facility at Tanuku, West Godavari Nature and details of the District, Andhra Pradesh during the period from action(s) taken, initiated or 2. July 13, 2026 to July 17, 2026. order(s) passed by the Authority At the conclusion of the inspection, the USFDA issued a Form 483 with six observations. The Company will respond to these observations within the stipulated time. Date of receipt of direction or order, including any ad- 3. interim or interim orders, or July 17, 2026 any other communication from the authority Details of the At the conclusion of the inspection, the USFDA violation(s)/ contravention(s) issued a Form 483 with six observations. The committed or alleged to be Company will respond to these observations within committed the stipulated time. A preliminary assessment of the observations indicates that all the observations are addressable with appropriate supporting documentation, corrective actions, technical justification and procedural enhancements. Impact on financial, Based on the nature of these observations, the operation, or other activities Company does not anticipate any impact to its 5. of the listed entity, manufacturing operations or exports to the Unites quantifiable in monetary States and other international markets. Accordingly, terms to the extent possible the Company does not expect any material impact on its operations or financial performance arising from this inspection. The Company remains committed to maintain the highest standards of quality and compliance with current Good Manufacturing Practices (cGMP).